TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15240605
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (4.1 mg/patch, twice a week; estimated delivery rate, 150 microg/d)
Study: 9615369
Drug: Ambulant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulant chemotherapy
Study: 8583218
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg/day for 8 days
Study: 8583218
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg/day for 15 days
Study: 8583218
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg/day for 30 days
Study: 2677294
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg intravenously at 6 hours of age and 0.1 mg/kg at 18 and 30 hours)
Study: 26238866
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and Adherence Inventory
Study: 16505505
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 10 units/day
Study: 15497664
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg capsules (Losefar 500 mg Capsules)
Study: 15497664
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg/5 mL suspension (Losefar 250 mg/5 mL Granules oral suspension)
Study: 15497664
Drug: Cefaclor (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (both formulations)
Study: 11266032
Drug: Parenteral vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral vitamin B12 (3 injections of 1 mg at 4-week intervals)
Study: 22965772
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (10 solitary and 4 multiple tumors, neo-adjuvant CTX followed by response-adapted RT)
Study: 22965772
Drug: RT-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT-only treatment group
Study: 15292626
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group
Study: 20850812
Drug: Prazosin (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.025 mg/kg nightly for 1 week, then increased to 2 divided doses)
Study: 20850812
Drug: Placebo (nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nightly for 1 week, then increased to 2 divided doses)
Study: 9798830
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment plus whirlpool (Group B)
Study: 9798830
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment only (Group A)
Study: 8033762
Drug: Increased methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased methadone dose (50-80 mg)
Study: 8033762
Drug: Decreased methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased methadone dose (80-50 mg)
Study: 2500273
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular injections (25 mg/kg body weight every week after a 4-week loading phase of 50 mg/kg/week)
Study: 2500273
Drug: Intravenous Intraglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Intraglobin F (300 mg/kg body weight every 3 weeks after initial treatment)
Study: 17342169
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine and modafinil
Study: 15538264
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (3 mg)
Study: 15538264
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil (50 mg)
Study: 9481967
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic with vibration
Study: 7575694
Drug: Tenidap 120
Normalized name: tenidap
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap 120 mg/day
Study: 3035913
Drug: Platinum (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum (60 mg/m2), doxorubicin (40 mg/m2), and VP-16 (150 mg/m2) (PAV)
Study: 3035913
Drug: Platinum (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum (60 mg/m2), 4'-epidoxorubicin (50 mg/m2), and VP-16 (150 mg/m2) (PEV)
Study: 24163364
Drug: Methylphenidate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.5 mg/kg)
Study: 11736883
Drug: Finrozole 3
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finrozole 3 mg tablets
Study: 11736883
Drug: Finrozole 9
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finrozole 9 mg tablets
Study: 11736883
Drug: Finrozole 30
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finrozole 30 mg tablets
Study: 11736883
Drug: Finrozole solution
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finrozole solution (dosage not specified)
Study: 11736883
Drug: Finrozole tablets
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finrozole tablets (general)
Study: 11736883
Drug: Finrozole 3
Normalized name: Fadrozole
DrugBank: Fadrozole (DB16832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finrozole 3 mg tablets vs 9 mg tablets
Study: 19491859
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 8 weeks)
Study: 23973688
Drug: simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin plus extended-release niacin (ERN, 1,500 to 2,000 mg/day)
Study: 17308269
Drug: AC (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC (doxorubicin 54 mg/m2 and cyclophosphamide 1.2 g/m2 IV every 3 weeks for six cycles)
Study: 17308269
Drug: A ->
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation "A ->". Drug abbreviations can vary and may not have a clear one-to-one mapping to a full generic name. Without more context about the specific drug or clinical trial, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A -> C (doxorubicin 40.5 mg/m2 IV days 1 and 2 every 3 weeks for four cycles followed by cyclophosphamide 2.4 gm/m2 IV every 2 weeks for three cycles)
Study: 19890256
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg daily
Study: 9741602
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) alone with an identical gel absent the steroid
Study: 25159818
Drug: HDACi 109
Normalized name: Hdac-in-4
DrugBank: CXD101 (DB16182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDACi 109 (RG2833) at doses ranging from 30mg/day to 240mg/day
Study: 22023516
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy followed by autologous stem cell transplantation
Study: 22023516
Drug: Complex karyotype,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex karyotype, translocation t(4;14), β(2)-microglobulin level > 2.5 mg/L
Study: 16762371
Drug: Olanzapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (up to 15 mg)
Study: 10227322
Drug: Outer-membrane protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer-membrane protein (OMP) meningococcal vaccine
Study: 6638856
Drug: Cephradine prophylaxis
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephradine prophylaxis (1 gram at induction of anaesthesia, followed by three postoperative doses of 1 gram at 6 hourly intervals)
Study: 30705033
Drug: Aggressive dose
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive dose escalation (group B)
Study: 30705033
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose escalation (group A)
Study: 19240522
Drug: Intraarticular sodium
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular sodium hyaluronate injections at weekly intervals for 3 weeks
Study: 7564973
Drug: Water placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water placebo + 280 mg nicotinic acid.l‐1 (WP + NA)
Study: 6927816
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Ro 13-5057
Study: 6927816
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Ro 13-5057
Study: 6927816
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ro 13-5057
Study: 27734549
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2.5 mcg·kg‐1)
Study: 27734549
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg·kg‐1)
Study: 21087463
Drug: Methylcellulose (bulking-agent)
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose (bulking-agent)
Study: 27156189
Drug: Azithromycin 10
Normalized name: azithromycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 10 mg/kg once daily for 3 days
Study: 30119284
Drug: Oral thyroxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thyroxin (5 μg/kg) administered 12 hours before surgery and once daily during ICU stay
Study: 22525511
Drug: Ultrasound Guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound Guided BC aspiration and corticosteroid injection (Group A)
Study: 22525511
Drug: Horizontal Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horizontal Therapy (Group B)
Study: 22525511
Drug: Ultrasound Guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound Guided BC aspiration and corticosteroid injection plus Horizontal therapy (Group C)
Study: 9311214
Drug: Lidocaine tape
Normalized name: lidocaine Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine tape applied to patients without preanesthetic medication (group N)
Study: 9311214
Drug: Lidocaine tape
Normalized name: lidocaine Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine tape applied to patients who received 0.1 mg.kg‐1 of diazepam (group D)
Study: 8346816
Drug: Ketorolac 30-60
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30-60 mg IV
Study: 8346816
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fentanyl 50-100 micrograms and ketorolac 30-60 mg IV
Study: 3787552
Drug: Isoprenaline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (400 microgram) given by inhalation after infusion
Study: 31559638
Drug: CGRP monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP monoclonal antibodies (mAbs)
Study: 30486868
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard in obesity treatment
Study: 25186159
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections for 2 years
Study: 19290686
Drug: Low-dose beverage
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose beverage (target blood alcohol level = .04)
Study: 19290686
Drug: High-dose beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beverage (target blood alcohol level = .08)
Study: 12351250
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g IV every 6 hours for 72 hours
Study: 9440727
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 160 mg/m2 I.V. every 3 weeks
Study: 9440727
Drug: Epirubicin (EPI)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPI) 160 mg/m2 I.V. every 3 weeks with DEX 1,000 mg/m2 I.V.
Study: 7985637
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg beta-carotene/d
Study: 2656087
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of mifepristone + 0.5 mg gemeprost vaginal pessary
Study: 2656087
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of mifepristone + 1 mg gemeprost vaginal pessary
Study: 29151374
Drug: MDG oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDG oil with 6 mg lutein (FloraGLO 20%)
Study: 3522894
Drug: Vidarabine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine 15 or 30 mg/kg/day
Study: 27532780
Drug: Low-concentration fish
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration fish sauce (2 g/L)
Study: 27532780
Drug: High-concentration fish
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration fish sauce (8 g/L)
Study: 18201872
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid (0.025%) treatment
Study: 23169946
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate)
Study: 6219964
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin phosphate combined with tretinoin gel 0.025%
Study: 6219964
Drug: Topical 1%
Normalized name: fluoride topical 1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1% clindamycin phosphate alone
Study: 6219964
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel 0.025% alone
Study: 31697990
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiation therapy (SAbR) boost, 28 Gy in 4 fractions
Study: 23571179
Drug: HBsAg‐1018 (investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg‐1018 (investigational hepatitis B surface antigen vaccine with phosphorothioate oligodeoxyribonucleotide adjuvant)
Study: 23571179
Drug: HBsAg‐Eng (commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg‐Eng (commercially available, alum‐adjuvanted hepatitis B vaccine)
Study: 21228629
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine stored at 2°C‐8°C (Group RIX4414-control)
Study: 21228629
Drug: RIX4414 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 vaccine stored at 37°C for 7 days (Group RIX4414-37°C)
Study: 22042952
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of androgen suppression therapy (AST)
Study: 17557956
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of androgen suppression therapy (AST)
Study: 11942874
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg (Group M10)
Study: 11942874
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg (Group M20)
Study: 9556321
Drug: High-calorie, high-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie, high-protein diet plus protein hydrolysate (70 g/day) for Group 2 patients (n = 7)
Study: 333644
Drug: Methylprednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (5 grams intravenously administered 2-4 hours prior to organ harvesting)
Study: 7270725
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of gluten daily for 5 weeks
Study: 30300282
Drug: 24-hour urinary
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour urinary creatinine excretion, TIMP‐2/mOsm, and total warm ischemia time on day 10
Study: 20961701
Drug: Perifracture site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perifracture site injection (PI) with local anesthetic mixture (ropivacaine, morphine, epinephrine); n = 22.
Study: 20961701
Drug: No perifracture
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perifracture site injection (no-PI); n = 22.
Study: 12736155
Drug: l-arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (1 g/min for 30 min) with insulin (6 mU x kg(‐1) x min(‐1) for 120 min)
Study: 12736155
Drug: l-arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (1 g/min for 30 min) without insulin
Study: 12736155
Drug: d-arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-arginine (1 g/min for 30 min)
Study: 11050518
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg i.v. (group 1)
Study: 11050518
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg i.v. (group 2)
Study: 11050518
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (droperidol + ondansetron)
Study: 26365210
Drug: Lifitegrast ophthalmic
Normalized name: lifitegrast ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifitegrast ophthalmic solution 5.0%, twice daily for 84 days
Study: 30112930
Drug: Lifitegrast ophthalmic
Normalized name: lifitegrast ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifitegrast ophthalmic solution 5.0%
Study: 23334069
Drug: Ponezumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponezumab (all doses)
Study: 21062338
Drug: Switching platform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching platform implants
Study: 15823764
Drug: Oxycodone 5
Normalized name: oxycodone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 5 mg
Study: 15823765
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet (Oxycodone 5 mg + Ibuprofen 400 mg)
Study: 11565840
Drug: TGF-β3 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGF-β3 (25 μg/mL) applied as mouthwash four times daily
Study: 2972167
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg 3 times daily)
Study: 31661809
Drug: Detoxification intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Detoxification intervention (exercise, sauna-induced sweating, crystalline nicotinic acid, and other supplements)
Study: 28434014
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 12 weeks)
Study: 15789980
Drug: Oral-B Indicator
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral-B Indicator toothbrush
Study: 11502643
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vesnarinone
Study: 2589534
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg im atropine (ATR)
Study: 11410074
Drug: Petadolex (Petasites
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petadolex (Petasites hybridus extract), 25 mg per capsule, 2 capsules twice daily for 12 weeks
Study: 1927240
Drug: 2% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mepivacaine with 0.1 mg fentanyl
Study: 19054193
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi Chuan training for 1 hour twice a week for 13 weeks
Study: 16907703
Drug: alpha2B C/A
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha2B C/A polymorphism in both whites and African-Americans taking beta-blockers
Study: 7654891
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg daily
Study: 9654800
Drug: School-based alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based alcohol and drug abuse prevention program
Study: 3046299
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E supplementation at doses up to 3200 mg/d (3200 IU/d)
Study: 3320325
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E supplementation
Study: 29651816
Drug: Weekly theoretical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly theoretical and hands-on guidance from dental hygienists on oral hygiene procedures and discussions on oral care routines
Study: 24178765
Drug: Alcohol (vodka
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (vodka 37.5% at a dose of 46.5 g ethanol)
Study: 24178765
Drug: Alcohol in
Normalized name: WATER/BENZYL ALCOHOL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol in combination with caffeine at a dose of 80 mg